221 related articles for article (PubMed ID: 14677095)
1. Immunodeficiency and Hodgkin's disease: treatment and outcome in the DAL HD78-90 and GPOH HD95 studies.
Niehues T; Schellong G; Dörffel W; Bucsky P; Mann G; Körholz D; Göbel U
Klin Padiatr; 2003; 215(6):315-20. PubMed ID: 14677095
[TBL] [Abstract][Full Text] [Related]
2. [Influence of age on treatment results in children and adolescents with Hodgkin's disease].
Balwierz W; Moryl-Bujakowska A; Depowska T; Klekawka T; Stanuch H; Matysiak M; Sopyło B; Kołakowska-Mrozowska B; Krenke K; Chybicka A; Raś M; Sońta-Jakimczyk D; Moszant A; Wachowiak J; Kaczmarek-Kanold M; Kowalczyk J; Odój T; Balcerska A; Drozyńska E; Wysocki M; Kołtan A; Krawczuk-Rybak M; Stolarska M
Przegl Lek; 2004; 61 Suppl 2():40-4. PubMed ID: 15686044
[TBL] [Abstract][Full Text] [Related]
3. Late valvular and other cardiac diseases after different doses of mediastinal radiotherapy for Hodgkin disease in children and adolescents: report from the longitudinal GPOH follow-up project of the German-Austrian DAL-HD studies.
Schellong G; Riepenhausen M; Bruch C; Kotthoff S; Vogt J; Bölling T; Dieckmann K; Pötter R; Heinecke A; Brämswig J; Dörffel W
Pediatr Blood Cancer; 2010 Dec; 55(6):1145-52. PubMed ID: 20734400
[TBL] [Abstract][Full Text] [Related]
4. Salvage therapy of progressive and recurrent Hodgkin's disease: results from a multicenter study of the pediatric DAL/GPOH-HD study group.
Schellong G; Dörffel W; Claviez A; Körholz D; Mann G; Scheel-Walter HG; Bökkerink JP; Riepenhausen M; Lüders H; Pötter R; Rühl U;
J Clin Oncol; 2005 Sep; 23(25):6181-9. PubMed ID: 16135485
[TBL] [Abstract][Full Text] [Related]
5. Late effects after therapy of Hodgkin's disease: update 2003/04 on overwhelming post-splenectomy infections and secondary malignancies.
Schellong G; Riepenhausen M
Klin Padiatr; 2004; 216(6):364-9. PubMed ID: 15565552
[TBL] [Abstract][Full Text] [Related]
6. Patterns of treatment failure in pediatric and young adult patients with Hodgkin's disease: local disease control with combined-modality therapy.
Krasin MJ; Rai SN; Kun LE; Merchant TE; Metzger ML; Kaste SC; Howard SC; Hudson MM
J Clin Oncol; 2005 Nov; 23(33):8406-13. PubMed ID: 16293871
[TBL] [Abstract][Full Text] [Related]
7. [Clinical results of 295 patients with Hodgkin's disease treated by chemotherapy-predominant comprehensive modality].
Huang HQ; Jiang WQ; Wang W; Xu GC; Zhang L; He YJ; Sun XF; Zhou ZM; Liu DG; Xu RH; Lin TY; Teng XY; Liu MZ; Su YS; Li YH; Lin XB; Guan ZZ
Ai Zheng; 2002 Dec; 21(12):1345-9. PubMed ID: 12520745
[TBL] [Abstract][Full Text] [Related]
8. [Use of risk-adapted programs of treatment of Hodgkin's disease in children and adolescents].
Kuleva SA
Vopr Onkol; 2008; 54(6):768-70. PubMed ID: 19241857
[TBL] [Abstract][Full Text] [Related]
9. [Preliminary results of thyroid function assessment in children and adolescents with Hodgkin's disease (HD) treated according to PGP-HD-97 protocol].
Moryl-Bujakowska A; Balwierz W; Sztefko K
Przegl Lek; 2004; 61 Suppl 2():81-4. PubMed ID: 15686053
[TBL] [Abstract][Full Text] [Related]
10. Lymphocyte-rich classical Hodgkin's lymphoma: clinical presentation and treatment outcome in 100 patients treated within German Hodgkin's Study Group trials.
Shimabukuro-Vornhagen A; Haverkamp H; Engert A; Balleisen L; Majunke P; Heil G; Eich HT; Stein H; Diehl V; Josting A
J Clin Oncol; 2005 Aug; 23(24):5739-45. PubMed ID: 16009944
[TBL] [Abstract][Full Text] [Related]
11. Risk-adapted, combined-modality therapy with VAMP/COP and response-based, involved-field radiation for unfavorable pediatric Hodgkin's disease.
Hudson MM; Krasin M; Link MP; Donaldson SS; Billups C; Merchant TE; Kun L; Billet AL; Kaste S; Tarbell NJ; Howard S; Friedmann AM; Hurwitz CA; Young JA; Marcus KC; Rai S; Cowan T; Weinstein HJ
J Clin Oncol; 2004 Nov; 22(22):4541-50. PubMed ID: 15542805
[TBL] [Abstract][Full Text] [Related]
12. The impact of central review and central therapy planning on the treatment of children and adolescents with Hodgkin lymphoma.
Lüders H; Rühl U; Marciniak H; Haerting J; Claviez A; Mann G; Schellong G; Wickmann L; Dörffel W
Eur J Cancer; 2014 Jan; 50(2):425-33. PubMed ID: 24157256
[TBL] [Abstract][Full Text] [Related]
13. [Treatment results of stage IA Hodgkin lymphoma: a report of 97 cases].
Tan WY; Hu DS; Zeng FY; Song QB; Hu S; Wei L; Zhou LQ
Ai Zheng; 2007 Dec; 26(12):1360-4. PubMed ID: 18076802
[TBL] [Abstract][Full Text] [Related]
14. [Diagnosis and treatment of Hodgkin's lymphoma (HL) in children].
Kolygin BA
Vopr Onkol; 2002; 48(3):269-73. PubMed ID: 12455347
[No Abstract] [Full Text] [Related]
15. Treatment of pediatric Hodgkin disease avoiding radiotherapy: excellent outcome with the Rotterdam-HD-84-protocol.
Hakvoort-Cammel FG; Buitendijk S; van den Heuvel-Eibrink M; Hählen K
Pediatr Blood Cancer; 2004 Jul; 43(1):8-16. PubMed ID: 15170884
[TBL] [Abstract][Full Text] [Related]
16. [Over 30-year experience of Polish Pediatric Leukemia/Lymphoma Study Group for treatment of Hodgkin's disease in children and adolescents: improvement curability and decrease of serious complications].
Balwierz W; Moryl-Bujakowska A; Depowska T; Klekawka T; Stanuch H; Matysiak M; Sopyło B; Kołakowska-Mrozowska B; Krenke K; Chybicka A; Raś M; Sońta-Jakimczyk D; Moszant A; Wachowiak J; Kaczmarek-Kanold M; Kowalczyk J; Odój T; Balcerska A; Drozyńska E; Wysocki M; Kołtan A; Krawczuk-Rybak M; Stolarska M
Przegl Lek; 2004; 61 Suppl 2():33-9. PubMed ID: 15688474
[TBL] [Abstract][Full Text] [Related]
17. Hodgkin disease in ataxia-telangiectasia patients with poor outcomes.
Sandoval C; Swift M
Med Pediatr Oncol; 2003 Mar; 40(3):162-6. PubMed ID: 12518345
[TBL] [Abstract][Full Text] [Related]
18. Final results of a prospective clinical trial with VAMP and low-dose involved-field radiation for children with low-risk Hodgkin's disease.
Donaldson SS; Link MP; Weinstein HJ; Rai SN; Brain S; Billett AL; Hurwitz CA; Krasin M; Kun LE; Marcus KC; Tarbell NJ; Young JA; Hudson MM
J Clin Oncol; 2007 Jan; 25(3):332-7. PubMed ID: 17235049
[TBL] [Abstract][Full Text] [Related]
19. Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group.
Behringer K; Breuer K; Reineke T; May M; Nogova L; Klimm B; Schmitz T; Wildt L; Diehl V; Engert A;
J Clin Oncol; 2005 Oct; 23(30):7555-64. PubMed ID: 16234521
[TBL] [Abstract][Full Text] [Related]
20. The concept of the GPOH-HD 2003 therapy study for pediatric Hodgkin's disease: evolution in the tradition of the DAL/GPOH studies.
Körholz D; Claviez A; Hasenclever D; Kluge R; Hirsch W; Kamprad F; Dörffel W; Wickmann L; Papsdorf K; Dieckmann K; Kahn T; Mauz-Körholz C; Dannenberg C; Pötter R; Brosteanu O; Schellong G; Sabri O
Klin Padiatr; 2004; 216(3):150-6. PubMed ID: 15175959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
